Eton Pharmaceuticals (ETON) Cost of Revenue (2019 - 2025)

Eton Pharmaceuticals (ETON) has 7 years of Cost of Revenue data on file, last reported at $8.2 million in Q4 2025.

• For the quarter ending Q4 2025, Cost of Revenue rose 58.21% year-over-year to $8.2 million; the trailing twelve-month figure through Dec 2025 stood at $37.2 million (up 138.53% YoY), and the FY2025 full-year result was $37.2 million, up 138.53% from the prior year.
• Cost of Revenue fell to $8.2 million in Q4 2025, from $14.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $14.6 million in Q3 2025 to a low of $174000.0 in Q2 2021.
• A 5-year average of $3.7 million and a median of $2.7 million in 2022 frame the typical range for Cost of Revenue.
• Peak annual rise in Cost of Revenue reached 1477.59% in 2022, while the deepest fall reached 46.6% in 2022.
• Tracing ETON's Cost of Revenue over 5 years: stood at $372000.0 in 2021, then surged by 474.73% to $2.1 million in 2022, then soared by 72.26% to $3.7 million in 2023, then soared by 40.4% to $5.2 million in 2024, then surged by 58.21% to $8.2 million in 2025.
• Business Quant data shows ETON's Cost of Revenue at $8.2 million in Q4 2025, $14.6 million in Q3 2025, and $7.0 million in Q2 2025.